Browsing by Author Schluep, T

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 8 to 16 of 16 < previous 
TitleAuthor(s)Issue DateViews
 
Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis
Proceeding/Conference:Journal of Hepatology
Walsh, RYuen, LHammond, RDeerain, JGiven, BSchluep, TYuen, MFChan, HLYLai, CLHamilton, JLau, JYFerrari, CGish, RGLocarnini, SA
2016
39
 
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLiu, SHKChan, HLYGiven, BDSchluep, THamilton, JLai, CLLocarnini, SALau, JYFerrari, CGish, RG
2017
13
 
RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLiu, SHKGiven, BSchluep, THamilton, JLai, CLLocarnini, SJackson, KLai, JYFerrari, CGish, RG.
2018
2
 
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
Journal:Science Translational Medicine
Wooddell, CIYuen, RMFChan, HLYGish, RGLocarnini, SAChavez, DFerrari, CGiven, BDHamilton, JKanner, SBLai, CLLai, JYNSchluep, TXu, ZLanford, RELewis, DL
2017
2
 
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
Journal:Clinical Pharmacology in Drug Development
Schluep, TLickliter, JHamilton, JLewis, DLLai, CLLau, JYNLocarnini, SAGish, RGGiven, BD
2017
8
 
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGGane, E
2019
10
 
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
Proceeding/Conference:Journal of Hepatology
Gane, ELocarnini, SLim, THStrasser, SSievert, WCheng, WThompson, AGiven, BSchluep, THamilton, JBiermer, MKalmeijer, RBeumont-Mauviel, MLenz, OCloherty, GWong, DKHSchwabe, CJackson, KFerrari, CLai, CLGish, RGYuen, RMF
2020
3
 
Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent
Journal:Antiviral Research
Gish, RGYuen, RMFChan, HLYGiven, BDLai, CLLocarnini, SALau, JYNWooddell, CISchluep, TLewis, DL
2015
43
 
Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC‐520, an RNAi drug targeting cccDNA derived HBV mRNA
Proceeding/Conference:Journal of Viral Hepatitis
Buter, EKWong, DKHJackson, KSchluep, TGersch, JKuhns, MCloherty, GALocarnini, SYuen, RMF
2018
4
Showing results 8 to 16 of 16 < previous